Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28423843 | 0.86 | CYP4F2 (0.43) | CYP4F2CYP4A11FDPSALDH1A1MEN1 | |
| SCHEMBL1261010 | 0.85 | ALDH1A1 (0.41) | CYP4F2CYP4A11FDPSALDH1A1MEN1 | |
| SCHEMBL27805166 | 0.84 | CYP4F2 (0.42) | CYP4F2CYP4A11FDPSALDH1A1MEN1 | |
| SCHEMBL5342373 | 0.79 | CYP4F2 (0.50) | CYP4F2CYP4A11FDPSALDH1A1MEN1 | |
| SCHEMBL29094913 | 0.77 | CYP4F2 (0.42) | CYP4F2CYP4A11FDPSALDH1A1SMPD1 | |
| SCHEMBL1728131 | 0.77 | ALDH1A1 (0.45) | CYP4F2CYP4A11ALDH1A1TSHR | |
| SCHEMBL4653162 | 0.75 | ALDH1A1 (0.43) | CYP4F2CYP4A11ALDH1A1TSHR | |
| SCHEMBL10814845 | 0.75 | CYP4F2 (0.39) | CYP4F2CYP4A11FDPSALDH1A1MEN1 | |
| SCHEMBL14852821 | 0.74 | CYP4F2 (0.50) | CYP4F2CYP4A11FDPSMEN1MAPT | |
| SCHEMBL28616760 | 0.74 | FDPS (0.39) | FDPSALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286655-B1 | TOPICAL COMPOSITION CONTAINING AT LEAST ONE ARYL OXIME, AND METHOD FOR THE PREPARATION THEREOF | MERCK PATENT GMBH (DE) | 2006-09-13 | — | — | EP | claimed |
| EP-1250043-B1 | EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN | AVON PROD INC (US) | 2004-09-08 | — | — | EP | claimed |
| US-20030176470-A1 | Topical composition containing at least one aryl oxime, and method for the preparation thereof | MERCK PATENT GMBH (DE) | 2003-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176470-A1 | Topical composition containing at least one aryl oxime, and method for the preparation thereof | MGLL, LIPA, GLO1 | CYP4F2 1967/4885CYP4A11 1653/4885FDPS 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.